Blog Entry
Medicare Drug Price Negotiations: Policy Implications Of The First 10 Drugs' Features
Nitzan Arad; Grace Hoover; Richard Evans; Mark McClellan
Health Affairs, 2024
Read MoreCommentary
The potential for artificial intelligence to transform healthcare: perspectives from international health leaders
Christina Silcox, Eyal Zimlichman, Katie Huber, Neil Rowen, Robert Saunders, Mark McClellan, Charles N. Kahn III, Claudia A. Salzberg, & David W. Bates
2024
Read MoreJournal Article
Measuring Clinical Benefit in Neonatal Randomized Clinical Trials: Challenges and Opportunities
An N. Massaro, MD, Beth Boyer, MPH, Mira Gill, MS, Dure Kim, PharmD, Matthew Laughon, MD, MPH, Michele Walsh, MD, Monica E. Lemmon, MD, Betsy Pilon, BA, and Gerri Baer, MD, on behalf of the Duke-Margolis/FDA Measuring Clinical Benefit in Neonatal RCTs Workshop Participants*
2024
Read MoreWhite Paper
Modernizing Medicare Risk Adjustment and Performance Measurement
Mark McClellan, Sara Debab, Frank McStay, Mark Japinga, and Rob Saunders
2024
Read More